At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intranasal Oxytocin in the Treatment of Autism
In Brief
A Phase 2 clinical trial evaluating Oxytocin and Placebo for Autism. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism
CountriesUnited States
CollaboratorsIcahn School of Medicine at Mount Sinai
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2007
Primary CompletionSep 2011
Study CompletionApr 2012
TodayJul 2026
First PostedJun 25, 2007
Enrollment StartJun 1, 2006
Primary CompletionSep 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.0 years ago
Interventions
Oxytocindrug
Intranasal Oxytocin
Placebodrug
Placebo Comparator